What’s the big deal about orphan drugs? Well, they form the fastest-growing segment of the pharma market and dominate FDA approvals for a start. The diseases they treat might be rare, but there is nothing niche about the commitment to their development – and the potential revenues as a result. For a quick spin round […]
Share:
What’s the big deal about orphan drugs? Well, they form the fastest-growing segment of the pharma market and dominate FDA approvals for a start. The diseases they treat might be rare, but there is nothing niche about the commitment to their development – and the potential revenues as a result.
For a quick spin round the highlights of this market and what it’ll look like by 2028, take a look at our new infographic.
Want to access the full report?
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
